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ABSTRACT: A one-pot, high-yield procedure for synthesiz-
ing lanthionine-containing peptides was developed. It relies on
the S-alkylation of cysteine-containing peptides with chiral
cyclic sulfamidates. The key feature of this approach is the use
of mild reaction conditions (only activated molecular sieves
are employed as the catalyst), leading to good chemo-
selectivity and excellent stereochemical control. The potential
of the new methodology has been investigated by synthesizing
the thioether ring of a natural lantibiotic, Haloduracin β.
Lantibiotics show promise as a new class of antibacterialagents that exhibit an extremely potent activity against a
broad spectrum of Gram-positive bacteria, including micro-
organisms resistant to conventional antibiotics.1 They contain
lanthionine (Lan), an unusual amino acid containing a
thioether group generated by post-translational modification
in ribosomes. Many efforts have been made to develop
methodologies for the chemical synthesis of lanthionine-
containing peptides, and one of the most challenging issues is
the introduction of multiple thioether bridges between side
chains, which is a unique structural feature of lantibiotics.2 In
this regard, the main hurdle is the generation of stereochemi-
cally pure lanthionine derivatives bearing protecting groups
that are compatible with the standard peptide synthesis
conditions and that allow the thioether ring formation. To
this aim, the most successful and widely employed synthetic
approach involves the direct incorporation of lanthionine (or
methyl lanthionine) into the growing peptide by using an
orthogonally protected lanthionine building block. Such a
building block can be obtained by reacting a N-protected
cysteine with an orthogonally protected cyclic sulfamidate in
the presence of a base, such as Cs2CO3 or 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU).3
Cyclic sulfamidates are considered versatile precursors in
organic synthesis for the preparation of various compounds of
biological interest.4 They are readily accessible to nucleophilic
attack by a variety of substrates, including thiolates from
cysteine groups.5 The reaction occurs via the SN2 mechanism
with inversion of the configuration at the sulfamidate O-
bearing carbon, providing regioselective and stereoselective
control of the process. The opening of the ring generates a N-
sulfate derivative that is easily hydrolyzed under acidic
conditions. When reacted with N- and C-protected cysteine
under basic conditions, five-membered cyclic sulfamidates,
derived from serine and threonine, yield protected derivatives
of (methyl)lanthionine.3 However, competing β-elimination
on cyclic sulfamidates is known to yield the corresponding
dehydroamino acid derivative. This side reaction represents a
potential limitation of base-catalyzed SN2 reactions, as it might
lead to an overall decrease of the reaction yield and to a
significant racemization, because of the possible Michael
addition of the sulfur nucleophile to the dehydrogenated
product.6
In this paper, we describe a synthetic approach to promote
the SN2 nucleophilic attack of a cysteine thiol group on cyclic
sulfamidates while preventing any β-elimination side reaction,
even in the presence of acidic hydrogens in the sulfamidate
ring. Our aim has been to develop a novel synthetic strategy to
introduce precursors within a linear peptide sequence able to
generate a thioether bridge (i.e., the typical structural motif of
lantibiotics). We rely on the S-alkylation of a cysteine residue
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already inserted in a peptide sequence by reaction with a cyclic
sulfamidate. The reaction is promoted by activated molecular
sieves (MS). Recently, we have shown that the MS-based
approach is very efficient for post-synthetic peptide mod-
ification via S-alkylation of cysteine-containing peptide
sequences.7 The dried aluminosilicate framework of the
activated MS may likely assist in sulfhydryl proton removal.7,8
To demonstrate this concept, peptide 1 (bearing N-acetyl
protection at the N-terminus and amide protection at the C-
terminus, to mimic a simple peptide sequence devoid of
potentially competing nucleophiles) was reacted with Boc-
SulfaSer-OMe, either in the presence of triethylamine (TEA),
as the base, or in the presence of activated MS (see Scheme 1).
Boc-SulfaSer-OMe is a protected sulfamidate derived from L-
serine that should convert the cysteine residue into an N- and
C-protected lanthionine residue. Under basic conventional
conditions (TEA, DMF, 1 h reaction time, rt), complete β-
elimination to the dehydroalanine derivative was observed,
while peptide 1 was recovered unreacted.
On the other hand, when model peptide 1 was reacted with
Boc-SulfaSer-OMe in the presence of activated 4 Å MS (T =
280 °C for 4 h under vacuum), the expected product was
recovered with 95% yield, as estimated by integration of the
HPLC peak of 1a, compared with that of the starting peptide
(see Table 1). The reaction conditions included DMF under
an argon atmosphere as the solvent, 1.2 equiv of Boc-SulfaSer-
OMe, stirring for 2 h at room temperature. The high reaction
yield confirmed the high reactivity exhibited by the cyclic
sulfamidate toward the thiol group even under the mild
reaction conditions we employed. It is important to underline
that the mild acidic conditions of the final purification step
(0.1% TFA in water) were sufficient to promote the complete
hydrolysis of the sulfate ester.9 Therefore, the incorporation of
protected lanthionine can be considered a one-pot synthesis.
Next, we considered compounds 2a−7a (Scheme 1, panel
B) to assess whether or not the conversion of cysteine to
lanthionine by our protocol could be performed in a
chemoselective way. As a matter of fact, these peptides bear
unprotected side-chain nucleophilic groups that might
potentially compete with cysteine S-alkylation. The excellent
yields of monoalkylated peptides 2a−7a (see Table 1) were
the first indication of the high chemoselectivity for S-alkylation.
The alkylation site was assessed by nuclear magnetic
resonance (NMR) spectroscopy. All peptide resonances,
including those from the lanthionine side chain, could be
assigned by means of 2D TOCSY and 2D ROESY NMR
spectra (see Figure 1 for representative NMR spectra, and SI
for comprehensive NMR data). The formation of lanthionine
was confirmed unambiguously by the detection of intra residue
ROE cross-peaks between Lan Hα and Hδ1/Hδ2, and between
Hε and Hβ1/Hβ2 (see Figure 1 for lanthionine atom
nomenclature). Integration of the signal of N-Boc and C-
OMe confirmed that all peptides, but 7a retained full
protection on the lanthionine side chain.
Unlike the other compounds, compound 7a (containing
methionine) was obtained as mixture of the Boc-protected
(∼20%) and deprotected (80%) lanthionine side chain.
Compound 7b was obtained by a reaction with the sulfamidate
bearing the more robust Cbz (benzyloxycarbonyl) protection
on the amino group, and OtBu protection on the carboxyl
group. The final product 7b fully retained the lanthionine N-
Cbz protection. However, as much as 66% of the product
missed the carboxyl OtBu protection (see the Supporting
Information (SI)). Further investigation is needed to assess
whether this effect is dependent on the lanthionine and
methionine relative position within the peptide sequence.
The lysine amino group and, to a lesser extent, the aspartic/
glutamic acid carboxylate group are known to be good
nucleophiles. Therefore, S-alkylation to introduce lanthionine
in the presence of these amino acids must be performed on
peptides bearing suitable masking groups. As an example, we
have synthesized compound 8a, starting from a peptide
precursor containing one lysine residue protected with ivDde
Scheme 1. Incorporation of Lanthionine in Peptide
Sequences
Table 1. Efficiency of the S-Alkylation Reaction To
Introduce Lanthionine in Peptidesa
aLegend: Lan = a lanthionine with Boc and OMe protections. Lan* =
a lanthionine with Cbz protection.
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(1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl,
a protecting group routinely used in solid-phase peptide
synthesis (see Scheme 2). The removal of the ivDde protecting
group from lysine after S-alkylation could be achieved by
adding 3% hydrazine directly in the reaction mixture used for
the S-alkylation (DMF), after a quick centrifugation step to
remove molecular sieves. Although the deprotection of lysine
to obtain the final product does not require a specific
additional step, the final yield is somewhat lower, compared
to that of compounds 1a−7a (recall Table 1).
Peptide 9a containing the cysteine residue sandwiched
between a histidine and a tryptophan residue was synthesized
to assess whether or not the close proximity of multiple
competing nucleophilic groups, such as the aromatic nitrogen
atoms of tryptophan and histidine, could affect the chemo-
selectivity for cysteine. As shown in Table 1, we obtained a
single final product having the expected mass, with a yield
comparable to that of compounds 1a−7a. 1H NMR character-
ization revealed a single final species retaining the full
protection on the lanthionine side chain. The detection of
intraresidue Lan Hα/Hδ and Lan Hε/Hβ ROE correlations
confirmed the formation of the lanthionine structure; thus,
there is a very high reaction chemoselectivity for cysteine
alkylation.
Once we assessed the high efficiency and chemoselectivity of
our approach to introduce lanthionine derivatives into peptide
sequences, we focused on the chemical synthesis of
Haloduracin β ring B. This molecule is a fragment of a
lantibiotic peptide from the Gram-positive bacterium Bacillus
halodurans. The native lantibiotic structure consists of two
post-translationally processed peptides, Halα and Halβ, acting
in synergy to provide bactericidal activity.10
The synthesis of Halβ ring B was first performed by a
solution-phase S-alkylation approach (see Scheme 3). The
precursor peptide Dde-VALCP-NH2 (10) was reacted with a
cyclic sulfamidate derived from D-serine, in order to match the
configuration of the natural Halβ, and was protected with OtBu
at the carboxyl group and with Cbz at the amino group (Cbz-
SulfaSer-OtBu). Cbz is widely used as an α-amino-protecting
group, for its stability to bases and mild acid treatments and
also for its versatile removal conditions; moreover, the
aromatic ring simplified the HPLC as well as the NMR
characterization of the final product. Peptide 10 Dde-VALCP-
NH2 was protected at the N-terminus with Dde instead of
Fmoc, to decrease the hydrophobicity of the protected peptide.
The S-alkylation reaction was performed in dimethyl
formamide (DMF) and in the presence of activated molecular
sieves as previously described. After the reaction, MS were
removed by mild centrifugation, and the DMF solution was
treated with 3% hydrazine to remove the peptide N-terminus
protection. The carboxylic function of the sulfamidate was
rescued from the tert-butyl group with 50% TFA in DCM.
After purification of the linear peptide, cyclization was
Figure 1. Expansions of 2D-TOCSY (bottom) and 2D ROESY (top)
NMR spectra of compound 5a with resonance assignment (DMSO-
d6, 300 K). The formation of lanthionine after S-alkylation is
demonstrated by the intraresidue ROE peaks as labeled in the ROESY
spectrum. An analogous pattern of lanthionine intraresidue ROE
cross-peaks was found for all compounds (see the Supporting
Information for complete NMR data).
Scheme 2. Incorporation of Lanthionine into a Lysine-
Containing Peptide
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performed with standard PyBOP/DIPEA chemistry in DMF
(see Scheme 3).11
With the aim of implementing the developed new strategy in
compliance with solid-phase peptide synthesis, we have
performed S-alkylation on a peptide precursor anchored on
resin (see Scheme 4).
The cysteine to be alkylated was protected with a highly acid
labile group, and the 4-methoxytrityl (Mmt), was easily
removed by treatment of the peptidyl resin with dilute
trifluoroacetic acid (1% TFA in DCM). Then, the peptidyl
resin, suspended in anhydrous DMF and in the presence of
activated 4 Å molecular sieves, was alkylated by adding 10
equiv of Cbz-SulfaSer-OtBu under stirring at room temperature
for 15 h. The final product (compound 10b) was obtained
with a yield comparable to that of the solution-phase approach
(Table 1). However, a much larger excess of the Cbz-SulfaSer-
OtBu (10 equiv) was required by the solid-phase approach,7d if
compared with that employed for the solution approach (1.2
equiv). Thus, we conclude that the latter approach is to be
preferred, because it is much less demanding, in terms of the
required amount of cyclic sulfamidate, especially if considering
that it is not commercially available.
In conclusion, an efficient, highly chemoselective, and
stereochemically controlled procedure to introduce lanthionine
derivatives in preformed peptide sequences has been
developed. It relies on the post-synthetic cysteine S-alkylation
by cyclic sulfamidates in the presence of activated molecular
sieves as the catalyst. The reaction conditions are mild enough
to prevent competing β-elimination that leads to dehydroala-
nine formation. Moreover, they are compatible with a range of
orthogonal peptide protecting groups on the sulfamidate
derivatives. This is a key feature of the proposed procedure,
since the selective removal of such orthogonal protections is
required to perform the subsequent cyclization step that leads
to the formation of a complete thioether ring structural motif.
As a demonstration of the proposed methodology, the
synthesis of Halβ ring B was successfully performed. It might
serve as a template for the design of synthetic approaches to
more-complex lantibiotics, having either sequential or inter-
locking rings. Further work to probe the potential of this
methodology is currently in progress. Namely, we are testing
sterically more demanding and less reactive sulfamidates,
which generally require a higher temperature to react with
thiolates.3a
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